-
Beckley Psytech Doses First Patients With Psilocin In Trial For Treatment Of Major Depression Disorder
Thursday, June 20, 2024 - 8:52am | 492The UK-based psychedelics medicine company Beckley Psytech announced Thursday that it has dosed its first patients in a Phase IIa study (NCT05434156) of ELE-101, a patent-protected synthetic formulation of psilocin benzoate to treat major depressive disorder (MDD). Psilocin is the active metabolite...
-
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
Friday, April 26, 2024 - 9:10am | 495Private psychedelics medicine company Beckley Psytech Ltd announced this week that the first patient has been dosed in the second part of its two-part Phase IIa study evaluating BPL-003 in patients with treatment-resistant depression (TRD). BPL-003 is its proprietary...